NeuroPace reports first-ever positive adjusted EBITDA and Nautilus next-gen smaller RNS in development for 2026
Summary
NeuroPace reported its first-ever positive adjusted EBITDA quarter in late 2025, validating the unit economics of the responsive neurostimulation business for epilepsy after more than a decade of commercial operation. The company's 2026 roadmap focuses on the "Nautilus" project — a next-generation, smaller form factor RNS device designed to make the cranial implantation procedure less invasive and suitable for earlier-in-treatment epilepsy patients. Additionally, NeuroPace plans to initiate first-in-human cases for a new lower back pain application (basivertebral nerve ablation) in early 2026, expanding from epilepsy into pain management backed by Zimmer Biomet's distribution network.
Why it matters
First-ever positive EBITDA for NeuroPace transforms the company's commercial narrative from a clinical-stage company burning cash to a financially self-sustaining neuromodulation business. For the closed-loop neuromodulation field, this milestone validates that RNS can build a sustainable commercial business — important evidence for investors evaluating the long-term commercial prospects of the next generation of closed-loop BCIs (Cadence, Motif, CorTec) that are years behind NeuroPace on the commercial timeline.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial